期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Cortex Moutan Inhibits Bladder Cancer Cell Proliferation and Expression of Angiogenic Factors
1
作者 Mei-Yi Lin cheng-huang shen +3 位作者 Su-Yin Chiang Syue-Yi Chen Yu-Shih Lin Cheng-Da Hsu 《Pharmacology & Pharmacy》 2014年第8期846-858,共13页
Metastases are the main cause of death among patients with bladder cancer, which is the second most common malignancy of the genitourinary tract and is highly prevalent in the southwestern region of Taiwan. Angiogenes... Metastases are the main cause of death among patients with bladder cancer, which is the second most common malignancy of the genitourinary tract and is highly prevalent in the southwestern region of Taiwan. Angiogenesis plays a critical role in tumor growth and metastasis processes and has relevance in disease recurrence, pelvic lymph node metastasis and poor prognosis. Cancer cells can produce several angiogenesis-stimulating factors involved in vascular growth, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and inflammatory cytokines such as interleukin (IL)-8. Common chemotherapeutic drugs for intravesical instillations usually cause major side effects, including urinary frequency, urinary urgency, cystitis, and hematuria. In order to identify a less cytotoxic therapeutic agent that can inhibit tumor cell proliferation, we examined the traditional Chinese herbal medicine Cortex Moutan—reported to have antibacterial, antiviral, anti-inflammatory, antithrombotic, and antitumor properties—for its effects on bladder cancer cell proliferation and expression of angiogenic factors. Our results revealed that Cortex Moutan exhibited high selectivity in inhibiting the growth of bladder cancer cells and also reduced the expression of angiogenesis-stimulating factors in those cells. Thus, we suggest that Cortex Moutan might be used as a cancer therapy drug for bladder’s intravesical chemotherapy in the future. 展开更多
关键词 CORTEX Moutan BFTC 905 CELLS TSGH 8301 CELLS Growth Inhibition VEGF BFGF IL-8
下载PDF
<i>Survivin</i>promoter rs9904341 polymorphism is associated with tumor stage and grade in patients with bladder cancer
2
作者 Zhon-Min Huang Yi-Te Chiang +5 位作者 Min-Che Tung Chia-Chang Wu Kuan-Chou Chen Ming-Te Huang Yuan-Hung Wang cheng-huang shen 《Advances in Bioscience and Biotechnology》 2013年第1期1-5,共5页
Survivin is an inhibitor of apoptosis protein and also plays a important role in the development of several malignancies. To investigate the association between survivin promoter –31 G/C (rs9904341) polymorphism and ... Survivin is an inhibitor of apoptosis protein and also plays a important role in the development of several malignancies. To investigate the association between survivin promoter –31 G/C (rs9904341) polymorphism and bladder cancer (BC) risk. A total of 200 pathologically confirmed BC cases and 200 unrelated cancer-free controls were recruited in Chiayi Christian Hospital from August 2002 to May 2009. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used to determine the –31 G/C polymorphism at survivin promoter region. There was a significant difference in the frequency distribution of survivin promoter –31 G/C polymorphism in BC cases as compared to controls. Among BC cases, individuals with the C/C genotype of survivin promoter have a significantly higher prevalence of invasive (T2-T4) or high-grade (G2-G3) tumors as compared to those who carried the G/G genotype. In conclusion, our findings suggest that the survivin promoter –31 G/C polymorphism was not only associated with clinical stage and pathological grade but also involved in the development of bladder cancer. 展开更多
关键词 SURVIVIN BLADDER Cancer POLYMORPHISM Apoptosis
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部